Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen
Proteine und Peptide

Human Diacylglycerol Kinase Epsilon (DGKe), Active Protein

Produktgrößen
50 ug
£1045,00
RPU54971-50UG
100 ug
£1276,00
RPU54971-100UG
1 mg
£5310,00
RPU54971-1MG
Über dieses Produkt
SKU:
RPU54971
Zusätzliche Namen:
DAGK5|DGK|Diglyceride kinase epsilon
Anwendung:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Weitere Details:
Human Diacylglycerol Kinase Epsilon (DGKe), Active Protein is a purified Prokaryotic Protein.
Formulierung:
Freeze-dried powder
Immunogen:
Diacylglycerol Kinase Epsilon (DGKe)
Molekulargewicht:
33kDa
Physischer Zustand:
freeze-dried
Reinheit:
>95%
Versandbedingungen:
Blue Ice
Lagerbedingungen:
-20[o]C Avoid freeze/thaw cycles.
Hersteller:
Biomatik
Typ:
Proteins, Peptides, Small Molecules & Other Biomolecules: Enzymes
Catalog Protein.JPG
DGKe (Diacylglycerol kinase epsilon) is an enzyme that mainly involved in the regeneration of phosphatidylinositol (PI) from diacylglycerol in the PI-cycle during cell signal transduction. PDHA1 (Pyruvate dehydrogenase E1 component subunit alpha) has been proven to be an interactor of DGKe through Affinity Capture-MS. Thus a binding ELISA assay was conducted to detect the interaction of recombinant human DGKe and recombinant human PDHA. Briefly, DGKe were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL DGKe were then transferred to PDHA-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-DGKe pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of DGKe and PDHA was shown in Figure 1, and this effect was in a dose dependent manner.
Figure 2. SDS-PAGE